文献速递消化道肿瘤与早癌消化内镜

T1期食管腺癌手术与内镜管理的比较:一项模型决策分析

Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-11-24

本研究采用决策分析马尔可夫模型,模拟75岁、Charlson合并症指数为0且患T1aN0M0或T1bN0M0食管腺癌的男性队列,比较食管切除术与系列内镜治疗的效果和成本效果。结果显示,T1a期内镜治疗获得的QALY更多且更具成本效果;T1b期选择取决于年龄和合并症。

要点

  • T1a期:内镜治疗QALY为5.22,食管切除术为4.95。
  • T1b期:食管切除术QALY为4.07,内镜治疗为3.85,增量成本效果比为156981美元。
  • 敏感性分析:80岁以上且合并症指数为1或2者,内镜治疗QALY更优。

核心结论

  • 在马尔可夫模型中,对于所有测试的年龄和合并症指数,T1a期食管腺癌内镜治疗比食管切除术获得更多QALY且更具成本效果。
  • T1b期食管腺癌的治疗选择取决于年龄和合并症,原因在于手术死亡率和非癌死亡的竞争风险。

研究设计与样本

  • 研究采用决策分析马尔可夫模型,模拟假设队列:75岁男性,Charlson合并症指数评分为0,患T1aN0M0或T1bN0M0食管腺癌,作为基础病例。
  • 模型比较食管切除术与系列内镜治疗的效果,并进行敏感性分析,基于诊断年龄60-85岁、合并症指数0-2和效用值。
  • 术后癌症特异性死亡率来自监测、流行病学和最终结果(SEER)医疗保险数据库。

主要发现

  • T1a基础病例:食管切除术未调整生命年为6.97,内镜治疗为6.81;食管切除术QALY为4.95,内镜治疗为5.22。
  • T1b基础病例:食管切除术未调整生命年为5.73,内镜治疗为5.01;食管切除术QALY为4.07,内镜治疗为3.85;增量成本效果比为156981美元。
  • 敏感性分析显示,对于80岁以上且合并症指数为1或2的患者,或当食管切除术后与内镜治疗后效用比低于0.875时,内镜治疗使QALY最优化。

关键数值与推荐

  • T1a基础病例:内镜治疗QALY为5.22,食管切除术为4.95。
  • T1b基础病例:食管切除术QALY为4.07,内镜治疗为3.85。
  • T1b基础病例增量成本效果比为156981美元。
  • 敏感性分析阈值:年龄超过80岁且合并症指数为1或2;食管切除术后与内镜治疗后效用比低于0.875。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although treatment of T1a esophageal adenocarcinoma (EAC) is shifting from esophagectomy to endoscopic therapy, T1b EACs are considered too high risk to be treated endoscopically. We investigated the effectiveness and cost effectiveness of esophagectomy vs endoscopic therapy for T1a and T1b EACs, and the effects of age and comorbidities, using a decision analytic Markov model. METHODS: We developed a model to simulate a hypothetical cohort of men 75 years old with Charlson comorbidity index scores of 0 and either T1aN0M0 or T1bN0M0 EAC, as a base case. We used the model to compare the effects of esophagectomy vs serial endoscopic therapy. We performed sensitivity analyses based on age at diagnosis of 60-85 years, comorbidity indices of 0-2, and utilities. Post-procedure cancer-specific mortality was derived from the Surveillance, Epidemiology, and End Results Medicare database. RESULTS: In the T1a base case, esophagectomy yielded more unadjusted life years than endoscopic therapy (6.97 vs 6.81), but fewer quality-adjusted life years (QALYs, 4.95 for esophagectomy vs 5.22 for endoscopic therapy). In the T1b base case, esophagectomy yielded more unadjusted life years than endoscopic therapy (5.73 vs 5.01) and QALYs (4.07 vs 3.85 for endoscopic therapy), but was not cost effective (incremental cost-effectiveness ratio $156,981). Sensitivity analyses showed endoscopic therapy optimized QALYs for patients more than 80 years old with a comorbidity index of 1 or 2, or if the ratio of post-esophagectomy to post-endoscopic therapy utilities was below 0.875. CONCLUSION: In a Markov model, we showed that endoscopic therapy of T1a EAC yields more QALYs and is more cost effective than esophagectomy for patients of all ages and comorbidity indices tested. In contrast, selection of therapy for T1b EAC depends on age and comorbidities, due to surgical mortality and the competing risk of non-cancer death.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chu JN, Choi J, Tramontano A, et al. Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clin Gastroenterol Hepatol. 2017. PMID: 29079222. doi:10.1016/j.cgh.2017.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。